Looks like a great quarterly report to me. Strong growth in product sales, great gross margin pct, expenses in line with growth, realigning toward core competencies, pipeline progress on potential blockbusters. ELN is firing on all cylinders.
The only thing which caught my eye was the statement on pending "approvables".
"With respect to Frovelan(TM), we are in the process of completing final matters arising on the FDA review and anticipate approval this quarter. With respect to Prialt(TM), we continue to press the FDA for the earliest possible approval of this important molecule."
Does anyone recall prior statements on Prialt status?? Is the above statement "backpedalling" as to timing??